Cited by 602Blood Coagulation and Thrombosis MechanismsAcute Myocardial Infarction ResearchBlood properties and coagulation

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Thögersen, Anna M., Jansson, Jan-Håkan, Boman, Kurt, Nilsson, Torbjörn K., Weinehall, Lars, Huhtasaari, Fritz, Hallmans, Göran·1998·Circulation

DOI 10.1161/01.cir.98.21.2241

Open this paper in CoChat — free account

Abstract

Background —In patients with established ischemic heart disease, prospective cohort studies have indicated that plasminogen activator inhibitor (PAI-1), the inhibitor of the fibrinolytic system, may predict cardiovascular events. So far, there have been no primary prospective studies of PAI-1. Methods and Results —The aim of the present study was to test whether plasma levels of PAI-1, tissue-type plasminogen activator (tPA), von Willebrand factor (vWF), and thrombomodulin (TM) could predict the occurrence of a first acute myocardial infarction (AMI) in a population with high prevalence of coronary heart disease by use of a prospective nested case-control design. Mass concentrations of PAI-1 and tPA were significantly higher for the 78 subjects who developed a first AMI compared with the 156 references matched for age, sex, and sampling time; for tPA, this increase was independent of smoking habits, body mass index, hypertension, diabetes, cholesterol, and apolipoprotein A-I. The ratio of quartile 4 to 1 for tPA was 5.9 for a patient to develop a first AMI. The association between tPA and AMI was seen in both men and women. Increased levels of vWF were associated with AMI in a univariate analysis. High levels of TM were associated with AMI in women but not in men. Conclusions —The plasma levels of PAI-1, tPA, and vWF are associated with subsequent development of a first AMI; for PAI-1 and tPA, this relation was found in both men and women. For tPA but not for PAI-1 and vWF, this association is independent of established risk factors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.98.21.2241

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coronary Plaque Disruption
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Endogenous tissue-type plasminogen activator and risk of myocardial infarction
Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C. H., & Stampfer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90998-v · Cited by 580
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
Juhan-Vague, I., Pyke, S., Alessi, M., Jespersen, J., Haverkate, F., & Thompson, S. G. (1996) · Circulation · doi:10.1161/01.cir.94.9.2057 · Cited by 551
von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.
Jansson, J., Nilsson, T., & Johnson, O. (1991) · Heart · doi:10.1136/hrt.66.5.351 · Cited by 356
Self-citation
Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex: Relationship to Elevated TPA Antigen in Patients With High PAI-1 Activity Levels
Chandler, W. L., Alessi, M. C., Aillaud, M. F., Henderson, P., Vague, P., & Juhan-Vague, I. (1997) · Circulation · doi:10.1161/01.cir.96.3.761 · Cited by 245

Show all 30 references

Research works printed but not linked: 10

10.1161/circ.83.1.1984895 · DOI
10.1161/circ.92.3.657 · DOI
10.1161/circ.94.9.2052 · DOI
10.1161/circ.90.1.8026046 · DOI
Amiral J, Adam M, Mimilia F, Larrivaz I, Chambrette B, Boffa MC. A new assay for soluble forms of thrombomodulin in plasma. Thromb Haemostas. 1991;947:65. Abstract.
10.1161/atv91.12.9.1525121 · DOI
10.1161/circ.88.5.8222095 · DOI
10.1161/circ.94.9.2057 · DOI
10.1161/atvb.15.9.1432 · DOI
10.1161/circ.96.3.761 · DOI

Sorted by citations

Items 501–597 of 597

Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects
Lottermoser, K., Hertfelder, H., Wehling, M., Schiermeyer, B., Vetter, H., & Düsing, R. (2000) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2000.066 · Cited by 3
Sex- and Strain-dependent Effects of Bisphenol: A Consumption in Juvenile Mice
Wyatt, B. N., & Gooding, J. R. (2016) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000694 · Cited by 3
“Elevated PAI-1 levels predispose individuals to atherosclerosis and myocardial infarction [55,56].”
Background
Applications of Infrared Spectroscopy and Microscopy in Diagnosis of Obesity
Mollaoglu, A. D., Ozyurt, I., & Severcan, F. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81216 · Cited by 3
Rye and Health
(2014) · Elsevier eBooks · doi:10.1016/c2015-0-06192-5 · Cited by 3
C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease
Arnold, N., & Köenig, W. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_5 · Cited by 3
[Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
Rabijewski, M., & Zgliczyński, W. (2007) · PubMed · Cited by 3
Tissue-type Plasminogen Activator (tPA)
Bachmann, F. (2001) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-56637-0_3 · Cited by 3
The fibrinolytic enzyme system : New markers of potential interest in cardiovascular disease
Nordenhem, A. (2005) · Figshare · Cited by 3
No Observed Difference in Inflammatory and Coagulation Markers Following Diets Rich in n-6 Polyunsaturated Fat vs Monounsaturated Fat in Adults With Untreated Hypercholesterolemia: A Randomized Trial
Prater, M. C., Scheurell, A. R., Paton, C. M., & Cooper, J. A. (2023) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2023.08.127 · Cited by 2
Tissu adipeux viscéral et thrombose
Juhan-Vague, I., & Alessi, M. (2008) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(08)71407-x · Cited by 2
Common Genetic Determinants of Coagulation and Fibrinolysis
Carter, A. M., Standeven, K. F., & Grant, P. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00060-4 · Cited by 2
Coagulation/Fibriolytic system and vascular disorder
Nagai, N. (2011) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.22.41 · Cited by 2
Obesity and Diabetes
Fatouros, I. G., & Mitrakou, A. (2012) · CRC Press eBooks · doi:10.1201/b12085-16 · Cited by 2
Molecular assessment of some cardiovascular genetic risk factors among Iraqi patients with ischemic heart diseases.
Mohammed, W. J., Al-Musawi, B. M. S., Oberkanins, C., & Pühringer, H. (2018) · Europe PMC (PubMed Central) · Cited by 2
Assessment of endogenous fibrinolysis in clinical practice using novel tests: ready for clinical roll-out?
Gue, Y. X., Ding, W. Y., Lip, G. Y. H., & Gorog, D. A. (2021) · SN Applied Sciences · doi:10.1007/s42452-021-04517-4 · Cited by 3
Acute Coronary Syndromes: From the Laboratory Markers to the Coronary Vessels
Palazzuoli, A., Iovine, F., Chiara, S., & Nuti, R. (2006) · Biomarker Insights · doi:10.1177/117727190600100013 · Cited by 6
Fibrinolytic factors in relation to anthropometry and incident type 2 diabetes.
Hernestål-Boman, J. (2014) · Cited by 2
Cardiovascular Disease and Insulin Resistance
Ajjan, R., & Grant, P. J. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_138 · Cited by 2
Biomarkers as Surrogates for Coronary Endothelial Dysfunction in Patients With Nonobstructive Coronary Artery Disease
Vani, A. K., Schwartzbard, A. Z., & WEINTRAUB, H. S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.010166 · Cited by 2
“Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of fibrinolysis with diurnal circadian variation, and higher serum PAI-1 levels are associated with greater myocardial infarction risk.(6,7) Soluble urokinase plasminogen activator receptor (suPAR) is a proinflammatory marker with evidence suggesting it can out…”
Background
Epidemiological and pathogenic aspects on cardiovascular disease in rheumatoid arthritis
Södergren, A. (2008) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2
Association between Sex and Platelet Function in Patients with Diabetes Mellitus Type II: A Systematic Review
Mikkelsen, R., Larsen, J. B., & Smidt, K. (2026) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2891-4643 · Cited by 1
Studies on the Role of Vitronectin and Plasminogen-Activator Inhibitor-1 Complexes Beyond Inhibiting Proteases: Binding to the Extracellular Matrix, Cell Interactions and Pathogenesis
Goswami, S. (2010) · Cited by 1
EFFECTS OF WEIGHT LOSS ON VISCERAL ADIPOSITY AND METABOLIC ADAPTATIONS IN DIABETIC VERSUS NON-DIABETIC WOMEN
Konz, E. C. (2005) · UKnowledge (University of Kentucky) · Cited by 1
Inflammation and haemostasis in the development and progression of peripheral atherosclerotic disease
Tzoulaki, I. (2007) · Cited by 1
Effects of Stress-Hemoconcentration on the Coagulation Cascade
Austin, A. W. (2011) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Non Alcoholic Fatty Liver: Should We Care?
Conceição, R. D. O., Oni, E., Laurinavicius, A. G., & Santos, R. D. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0384-7 · Cited by 1
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination
Tsikouris, J. P., Cox, C. D., Simoni, J. M., Seifert, C. F., Peek, M. C., & Meyerrose, G. E. (2006) · Coronary Artery Disease · doi:10.1097/00019501-200608000-00007 · Cited by 1
Plasminogen Activator Inhibitor-1, Body Fat and Insulin Action in Aging Women.
McMillin, S. L., & Ryan, A. S. (2014) · PubMed · Cited by 1
Fibrinolytic, Platelets and Endothelial Microparticles Abnormalities among Obese Type 2 Diabetic Patients
Al-Dahr, M. H. S. (2017) · Advanced Research in Gastroenterology & Hepatology · doi:10.19080/argh.2017.03.555620 · Cited by 1
Viral pathogens as novel activators of procoagulant signalling
Krötz, F. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-04-0265 · Cited by 1
Akut Koroner Sendromlu Hastalarda Plazma von Willebrand Faktör Düzeyi ile Koroner Arter Hastalığı Ciddiyeti Arasındaki İlişkisi
Taşcanov, M. B., & Güngören, F. (2019) · Harran Üniversitesi Tıp Fakültesi Dergisi · doi:10.35440/hutfd.623232 · Cited by 1
Beyond the established risk factors of myocardial infarction : lifestyle factors and novel biomarkers
Wennberg, P. (2009) · DiVA at Umeå University (Umeå University) · Cited by 1
ADIPOSE TISSUE AS AN ENDOCRINE ORGAN: PATHOPHYSIOLOGICAL AND THERAPEUTIC IMPLICATIONS
Pérez-Mayorga, M. (2007) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 8
Fibrinolytic parameters in young adults: the Floren-teen (Florence Teenager) Study
Prisco, D., Fedi, S., Brunelli, T., Chiarugi, L., Gianni, R., Santoro, E., Cappelletti, C., Pepe, G., Gensini, G. F., & Abbate, R. (2000) · Fibrinolysis and Proteolysis · doi:10.1054/fipr.2000.0084 · Cited by 1
Tkankowy aktywator plazminogenu (t-PA) i jego inhibitor typu 1 (PAI-1) u chorych z ostrym zawałem serca
Bujak, R., Sinkiewicz, W., Błażejewski, J., & Żekanowska, J. B. I. E. (2002) · Via Medica Journals · Cited by 1
Changes in Hemostasis and Lipid Metabolism in Postmenopausal Women Receiving Hormone Replacement Therapy: Effects of Natural and Synthetic Progestogens
Teng, L.-F., Chen, F., & Lee, N. (2004) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(09)60061-9 · Cited by 1
Are thiazolidinediones good or bad for the heart?
Taylor, A. M., & McNamara, C. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0009-8 · Cited by 1
“Further, endothelial release of plasminogen activator inhibitor-1 is increased and contributes to thrombosis and progression of the atherosclerotic lesion [ 13 ].”
Background
Impaired fasting glycaemia vs. impaired glucose tolerance: two sides of the same coin with implications for cardiovascular risk
Lim, H. S., & Lip, G. Y. H. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01232.x · Cited by 1
Coronary release of t-PA
Österlund, B. (2002) · Cited by 1
Correction: Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population
Penrod, N. M., Poku, K. A., Vaughn, D. E., Asselbergs, F. W., Brown, N. J., Moore, J. H., & Williams, S. M. (2011) · PLoS ONE · doi:10.1371/annotation/2501cac9-f313-406f-919b-314f12b43516 · Cited by 1
Thrombotic Vascular Disease
Moll, S., & White, G. (2005) · Humana Press eBooks · doi:10.1007/978-1-59259-878-6_27 · Cited by 1
Association of Thrombotic Disease with Genetic Polymorphism of Haemostatic Genes: Relevance to Pharmacogenetics
Tuddenham, E. G. D. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-06214-2_12 · Cited by 1
Impairment of Endothelial Thromboprotective Function by Haemodynamic and Inflammatory Stress Implications for hypertensive disease
Ulfhammer, E. (2007) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Key References: Basic Fibrinolysis and Thrombolysis Selected References: 1987–1997
Andreotti, F., Marco, E. D., & Patti, G. (2000) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1018608614612
How and Why Do We Diagnose Metabolic Syndrome
Saito, K., Ishizaka, N., & Nagai, R. (2006) · Ningen dock : official journal of the Japanese Society of Human Dry Dock · doi:10.11320/ningendock2005.20.1
Fibrinolysis, inflammation and cardiovascular disease; Epidemiological studies on Plasminogen activator inhibitor-type 1 and C-reactive protein
Hoekstra, T. (2003) · doi:10.18174/192224
Hemostasis and microvascular function in type 1 diabetes : effects of treatment with statin and aspirin
Tehrani, S. (2013) · Figshare
Metabolic Syndrome and its Impact on Cardiovascular Disease
Larry, J. A. (2013) · doi:10.1002/9781118395318.ch25
BLOOD PRESSURE ELEVATION: IMPACT ON CARDIOVASCULAR STRUCTURE AND ENDOGENOUS FIBRINOLYSIS
Ridderstråle, W. (2008) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Relationships among Cynical Hostility, Metabolic Syndrome, and Cardiac Structure and Function in Multi-Ethnic Post-Myocardial Infarction Patients: A Structural Modeling Approach
Wachowiak, P. S. (2009)
The TNF-receptor subtype 2 mediates prothrombotic effects in vivo
Pircher, J. (2011) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.13565
Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells
Suzuki, Y. (2009) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.20.428
Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in normal subjects
Lottermoser, K. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01153-5
Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Allele Polymorphisms and NIDDM(Non-Insulin Dependent Diabetes Mellitus) Risk Factor for Early Onset Myocardial Infarction
Onrat, E. (2014) · International Journal of Cardiovascular Research · doi:10.4172/2324-8602.1000179
The role of the fibrinolytic system in arterial and venous thrombosis
Meltzer, M. E. (2010) · Utrecht University Repository (Utrecht University)
Determinants of adverse events during oral anticoagulant treatment
Lind, M. M. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Actividad del lupus eritematoso sistémico y marcadores sanguíneos asociados a aterosclerosis
Urquizu-Padilla, M. (2008) · TDX (Tesis Doctorals en Xarxa)
Artrite Reumatóide e Doenças Cardiovasculares Rheumatoid Arthritis and Cardiovascular Disease
Torigoe, D. Y., & Laurindo, I. M. M. (2006)
Diabetes Mellitus and Cardiovascular Risk : epidemiology, etiology and intervention
Rautio, A. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
ENTERO-OMENTECTOMIA ADAPTATIVA COMO TRATAMENTO AUXILIAR DO DIABETES MELLITUS TIPO 2
Milléo, F. Q. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Hemostatic risk marker associated with cardiovascular events in metabolic syndrome
Bodanese, L., Wiehe, M., Jardim, J., Bonato, C., & Munhoz, E. (2015) · International Journal of Cardiovascular Sciences · doi:10.5935/2359-4802.20150020
[Plasminogen activator inhibitor-1 (PAI-1): pathogenetic role in coronary disease].
Młynarska, A., Waszyrowski, T., & Kasprzak, J. D. (2007) · PubMed
Obesity, Nutrigenomics, Metabolic Syndrome, and Type 2 Diabetes
Heber, D. (2007) · Oxidative stress and disease · doi:10.1201/9781420043792.ch7
Insulin Resistance, Obesity, Body Fat Distribution, and Risk of Cardiovascular Disease
Shetty, G. K., & Mantzoros, C. S. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420018905.003
The effect of acute aerobic exercise on hemostasis in obstructive sleep apnea patients
Martin, R. A. (2016) · JMU Scholoraly Commons (James Madison University)
Calcium Metabolism and Vascular Tone in Experimental Hypertension and Renal Failure
Jolma, P. (2003) · Tampere University Institutional Repository (Tampere University)
Intakes of Whole and Refined Grains and Dietary Fibre In Relation to Plasma Inflammatory Protein Concentrations
Masters, R. C. (2009) · TSpace (University of Toronto)
Atherosclerosis
Pajukanta, P., Tan, K. T., & Liew, C. (2007) · Wiley eBooks · doi:10.1002/9780470691977.ch6
Late complications of the treatment of patients with germ cell tumors
Danielyan, D. G., Salimova, A. A., Bulanov, A., Fedyanin, M. Y., & Tryakin, A. A. (2020) · Cancer Urology · doi:10.17650/1726-9776-2020-16-2-152-161
“Имеются работы, результаты которых подтверждают наличие связи последних с повышенным риском ишемической болезни сердца [3, 4].”
Non-Alcoholic Fatty Liver Disease and its Interplay with Various Metabolic Disorders
Papy, I. S., Cheng, X., Le, G., & Islam, M. S. (2020) · RePEc: Research Papers in Economics · doi:10.5281/zenodo.3708526
Bibliography
(2003) · Scandinavian Journal of Public Health · doi:10.1080/14034950310001478
References
(2018) · Wiley eBooks · doi:10.1002/9781118829875.refs
Emerging or Historical Endocrine and Metabolic Tests with Potential Clinical Utility
(2009) · CRC Press eBooks · doi:10.1201/9781420079364.ch13
References
(2005) · Wiley eBooks · doi:10.1002/9780470774663.refs
Pathophysiologie der Atherosklerose
Rodionov, R. N., Jarzebska, N., Morawietz, H., Goettsch, C., Hohenstein, B., Kopaliani, I., Julius, U., Tselmin, S., Lawall, H., & Weiss, N. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-61379-5_15-1
Pathophysiologie der Atherosklerose
Rodionov, R. N., Jarzebska, N., Morawietz, H., Göttsch, C., Hohenstein, B., Kopaliani, I., Julius, U., Tselmin, S., Lawall, H., & Weiss, N. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60880-7_15
Dysfunctional HDL-cholesterol: a potential link between high levels of HDL-cholesterol and cardiovascular disease?
Taylor, P. (2013) · Otago University Research Archive (University of Otago)
Antecedents, characterisation and validity of cardiovascular disease biomarkers amongst South Asians in the UK
Chackathayil, J. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Peripheral Arterial Disease: Incidence, Risk Factors, and Diagnosis
Althouse, A. D. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Additional file 1 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687174
Additional file 7 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687192
Additional file 3 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687180
Additional file 4 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687183
Additional file 6 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687189
Additional file 2 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687177
Additional file 5 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687186
Additional file 8 of Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Figshare · doi:10.6084/m9.figshare.19687195
4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status
Zhang, X., & Guo, X. (2026) · Thrombosis Journal · doi:10.1186/s12959-026-00828-x
“PAI-1 is an important part of the fibrinolysis system in the body and a major regulator of plasminogen activation [12, 13].”
Déterminants de l'athérothrombose chez le patient diabétique de type II
Ghannudi, S. E. (2013) · theses.fr (ABES) · doi:10.70675/bfcde275z318dz4944z883azc15c9350b7ac
Mechanisms of S-nitrosothiols intestinal permeability and NO store formation within vascular wall to improve NO oral delivery systems
Zhou, Y. (2019) · theses.fr (ABES) · doi:10.70675/baa75bb0z839cz4fc3zad54z3025537b1644
Stade prodromal de la maladie d'Alzheimer : nature des déficits mnésiques et liens avec les biomarqueurs d'imagerie.
Tomadesso, C. (2018) · theses.fr (ABES) · doi:10.70675/7fad6418zff81z49c7z984dz63aa2e44d7fc
Strategies to control biodistribution and activitiy of new bioactive materials and molecules
Sobska, J. (2021) · theses.fr (ABES) · doi:10.70675/205e3e32z8d6bz4fcdz8ef9ze01810e99816
Effect of Interleukin-6 Receptor Inhibition by Tocilizumab on Platelet Activation and Markers of Thrombus Formation: A Substudy of the ASSAIL-MI Trial
Ueland, T., Dahl, T. B., Michelsen, A. E., Kleveland, O., Andersen, G. Ø., Anstensrud, A. K., Huse, C., Woxholt, S., Broch, K., Gullestad, L. L., et al. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.323587
Genetic Markers of Hemostatic Factors
Girelli, D., Olivieri, O., & Corrocher, R. (2001) · Developments in cardiovascular medicine · doi:10.1007/978-94-010-1019-1_7
The Hunt for the Ideal Thrombolytic Agent: Mutants of tPA and uPA, Chimera of Both Molecules, Fibrolase
Verstraete, M. (2001) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-56637-0_19
Clinical and Research Applications of Markers of Thrombosis
Patel, M. R., & Becker, R. C. (2006) · Humana Press eBooks · doi:10.1007/978-1-59745-051-5_26
“Finally, in patients without a previous MI, increased PAI-1 levels in men were found to correlate with future MI ( 78 ).”
Background
Drug Therapy and Follow-Up
Eandi, M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7222-4_19
“[1 33 ] 25 3 Pr av as ta tin 1 0/ di et − 26 + 29 % D P I − 7/ + 27 (P = 0 .”
Background

Authors: Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G.
Affiliations: From the Department of Medicine (A.M.T.), Department of Clinical Chemistry (T.K.N.), and Departments of Nutritional Research and Pathology (G.H.), Umeå University Hospital; Department of Medicine-Geriatric, Skellefteå County Hospital (J.-H.J., K.B.) and Department of Epidemiology and Public Health (L.W.), University of Umeå; and Department of Medicine, Luleå Hospital (F.H.), Sweden.
University Hospital of Umeå (SE)
ORCID: Boman, Kurt
Weinehall, Lars
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1998-11-24
Volume: 98
Issue: 21
Pages: 2241-2247
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.98.21.2241
OpenAlex: W1976057876
Cited by: 602
References: 30
Citations by year: 2026: 3 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 19 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 14 · 2017: 7 · 2016: 17 · 2015: 12 · 2014: 27 · 2013: 20 · 2012: 19
FWCI: 10.91
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Umeå Universitet
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Hematology › Blood properties and coagulation
Keywords: plasminogen activator inhibitor-1, tissue plasminogen activator, acute myocardial infarction, von Willebrand factor, thrombomodulin, fibrinolysis, coronary artery disease, cardiovascular risk prediction, sex differences, plasma biomarkers
MeSH terms: Adult, Age Factors, Female, Fibrinolysis, Humans, Middle Aged, Myocardial Infarction, Tissue Plasminogen Activator, Predictive Value of Tests, Prospective Studies, Risk Factors, Sex Factors, Sweden, Biomarkers, Plasminogen Inactivators, Incidence, Case-Control Studies, Dehydroepiandrosterone Sulfate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks